What's Next For NRx Pharma As FDA Denies Breakthrough Therapy Tag For COVID-19 Therapy

  • The FDA has denied NRx Pharmaceuticals Inc's NRXP Breakthrough Therapy designation (BTD) request for Zyesami (aviptadil).
  • The request for BTD was submitted based on a post-hoc subgroup analysis of patients who, in addition to aviptadil or placebo, were also treated with Gilead Sciences Inc's GILD remdesivir and whose respiratory failure due to critical COVID-19 continued to progress.
  • Related: Why NRX Pharmaceuticals Shares Are Trading Lower During Premarket On Thursday?
  • The company emphasized its focus on the company's NRX-101 BTD compound for Bipolar Depression associated with Suicidality.
  • It expects topline data from the Phase 2 study of NRX-101 in patients with bipolar depression with sub-acute suicidal ideation (SSIB) by the end of the year. 
  • "Given ZYESAMI's mechanism and its well-characterized safety profile, NRx Pharmaceuticals will further evaluate the options for its use in other high unmet pulmonary and non-pulmonary indications," said Robert Besthof, interim CEO of NRx Pharma. 
  • Price Action: NRXP shares are down 0.85% at $0.57 during the premarket session on the last check Monday.

Posted In: BriefsCOVID-19 CoronavirusBiotechNewsPenny StocksHealth CareFDAGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.